Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$150.49
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,355,487,232.00
EPSttm : 4.92
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$150.49
3.28%
$4.79

Float Short %

13.67

Margin Of Safety %

-10

Put/Call OI Ratio

1.99

EPS Next Q Diff

-0.04

EPS Last/This Y

1.8

EPS This/Next Y

3.39

Price

150.49

Target Price

205.82

Analyst Recom

1.17

Performance Q

20.11

Relative Volume

0.67

Beta

0.66

Ticker: KRYS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25KRYS147.71.640.1012789
2025-07-28KRYS152.911.631.6412827
2025-07-29KRYS152.111.640.2012960
2025-07-30KRYS153.151.649.5012982
2025-07-31KRYS153.921.650.1913011
2025-08-01KRYS156.921.640.3213025
2025-08-04KRYS134.881.590.3913234
2025-08-05KRYS137.351.490.2113610
2025-08-06KRYS136.061.531.0213546
2025-08-07KRYS136.241.531.2913520
2025-08-08KRYS138.781.531.2513505
2025-08-11KRYS137.591.530.0313509
2025-08-12KRYS143.711.500.2113649
2025-08-13KRYS149.51.480.2114041
2025-08-14KRYS150.451.460.0114197
2025-08-15KRYS150.261.470.0914191
2025-08-18KRYS146.461.480.346272
2025-08-19KRYS143.741.541.506519
2025-08-20KRYS145.881.54196.506536
2025-08-21KRYS145.521.992.007710
2025-08-22KRYS150.491.995.897723
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25KRYS147.6149.431.86.11
2025-07-28KRYS153.4253.642.66.23
2025-07-29KRYS152.0853.633.86.23
2025-07-30KRYS153.2253.636.46.23
2025-07-31KRYS153.8753.635.76.23
2025-08-01KRYS156.9853.638.86.23
2025-08-04KRYS134.9453.67.66.23
2025-08-05KRYS137.3553.638.46.23
2025-08-06KRYS135.95-11.4-2.25.06
2025-08-07KRYS136.10-11.4-0.25.06
2025-08-08KRYS138.66-13.03.14.92
2025-08-11KRYS137.68-13.0-1.64.92
2025-08-12KRYS143.62-13.07.74.92
2025-08-13KRYS149.34-13.06.84.92
2025-08-14KRYS150.39-13.00.94.92
2025-08-15KRYS150.37-13.0-0.34.92
2025-08-18KRYS146.31-13.0-5.14.92
2025-08-19KRYS143.96-13.0-3.34.92
2025-08-20KRYS146.08-13.02.34.92
2025-08-21KRYS145.61-13.0-0.74.92
2025-08-22KRYS150.49-13.05.64.92
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25KRYS-4.70-1.3612.66
2025-07-28KRYS-4.70-1.0712.66
2025-07-29KRYS-4.70-1.0712.66
2025-07-30KRYS-4.70-1.0712.66
2025-07-31KRYS-4.70-1.0712.66
2025-08-01KRYS-4.70-1.0712.66
2025-08-04KRYS-4.70-0.0512.66
2025-08-05KRYS-4.70-0.0512.66
2025-08-06KRYS-4.70-0.0512.66
2025-08-07KRYS-4.69-0.0512.64
2025-08-08KRYS-4.69-0.0512.64
2025-08-11KRYS-4.690.0112.64
2025-08-12KRYS-4.690.0113.67
2025-08-13KRYS-4.690.0113.67
2025-08-14KRYS-4.690.0113.67
2025-08-15KRYS-4.690.0113.67
2025-08-18KRYS-4.672.3713.67
2025-08-19KRYS-4.692.3713.67
2025-08-20KRYS-4.692.3713.67
2025-08-21KRYS-4.692.3713.67
2025-08-22KRYS-4.692.3713.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.29

Avg. EPS Est. Current Quarter

1.12

Avg. EPS Est. Next Quarter

1.25

Insider Transactions

-4.69

Institutional Transactions

2.37

Beta

0.66

Average Sales Estimate Current Quarter

93

Average Sales Estimate Next Quarter

105

Fair Value

135.27

Quality Score

89

Growth Score

36

Sentiment Score

74

Actual DrawDown %

31.4

Max Drawdown 5-Year %

-53.4

Target Price

205.82

P/E

30.61

Forward P/E

19.18

PEG

0.53

P/S

12.13

P/B

4.18

P/Free Cash Flow

23.49

EPS

4.92

Average EPS Est. Cur. Y​

4.92

EPS Next Y. (Est.)

8.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

40.85

Relative Volume

0.67

Return on Equity vs Sector %

-10.6

Return on Equity vs Industry %

2.3

EPS 1 7Days Diff

-1.3

EPS 1 30Days Diff

-0.95

EBIT Estimation

5.6
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading